Skip to main content
SpringerLink
Log in

Not enough evidence on PARP inhibitors for ovarian cancer

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Institute for Clinical and Economic Review. Institute for Clinical and Economic Review's Final Report Confirms Inadequate Evidence to Compare Outcomes of PARP inhibitors for Ovarian Cancer, Highlights Poor Cost-Effectiveness, Particularly for Maintenance Therapy. Internet Document : 29 Sep 2017. Available from: URL: https://icer-review.org/announcements/ovarian-cancer-parp-final/

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Not enough evidence on PARP inhibitors for ovarian cancer. PharmacoEcon Outcomes News 788, 6 (2017). https://doi.org/10.1007/s40274-017-4374-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4374-0

Search

Navigation